Companies · Biotechnology

Juneau Biosciences, LLC

Salt Lake City · Biotechnology

Diligence memoA one-page analyst read on Juneau Biosciences, LLC — recommendation, valuation, rhythm, risks.
$8.1M
Total raised · real
5
Rounds
2.0×
Latest step-up
Top 49%
Sector rank · raised
Seed
Latest stage · inferred · Tue Jul 19 2011 00:00:00 GMT+0000 (Coordinated Universal Time)

Juneau Biosciences, LLC looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.51× the median modeled value of Seed Biotechnology companies in 2010–2012 (151 peers) — value vs value, same stage and era.
Dormant
  • Last raise 15.0 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Juneau Biosciences, LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
17.3 yr record
Peak capital year was 2010 with $4.0M across 2 filings.
Market position
ahead of 52% of Biotechnology peers
Capital scale is ahead of 52% of Biotechnology peers; modeled value is above 43% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2010: $4.0M across 2 filings.
  • Largest single filing was $3.8M on 2010-05-21.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Juneau Biosciences, LLC is one of 4293 Biotechnology companies tracked from Salt Lake City. By capital raised it ranks mid-pack (ahead of 52% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeed · 2009-03-23 Raised $2.6M (real) Modeled valuation $115M (est)$2.6M$115MSeed2009Seed · 2010-05-21 Raised $3.8M (real) Modeled valuation $167M (est)$3.8M$167MSeed2010Seed · 2010-05-21 Raised $250K (real) Modeled valuation $11M (est)$250K$11MSeed2010Seed · 2011-05-31 Raised $500K (real) Modeled valuation $22M (est)$500K$22MSeed2011Seed · 2011-07-19 Raised $1.0M (real) Modeled valuation $44M (est)$1.0M$44MSeed2011+$3.8M+$250K+$500K+$1.0MCumulative $8.1M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$2.6M · 2009
Seed extension$3.8M · 2010
Seed extension$250K · 2010
Seed extension$500K · 2011
Seed extension$1.0M · 2011

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$44.4M
Base estimate est.
$720K
Conservative case
$348.4M
Upside case
$5.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $115.4M · 2009-03-232009Seed · modeled $167.0M · 2010-05-21Seed · modeled $11.1M · 2010-05-21Seed · modeled $22.2M · 2011-05-31Seed · modeled $44.4M · 2011-07-192011
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
6.0 yr
Elapsed time used
14.9 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
7 mo
Avg between rounds
$3.5M/yr
Capital velocity
17.3 yr
On record since
2009
First round
5
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.1× above median
This company$8.1M
Sector median$7.2M
Latest round — vs other Seed rounds in sector (real $, this stage) 0.6× of median
This company$1.0M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 0.7× of median
This company$44.4M
Sector median$64.2M

Raised more than 52% of sector peers (real $). Modeled value above 43% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #123 of 151.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0MCapital raised (log)Denali Medical II, Inc. · Seed Raised $4.0M · modeled $177.6M (est)Signum Biosciences, Inc. · Seed Raised $4.0M · modeled $177.6M (est)Health Elements, LLC · Seed Raised $4.0M · modeled $177.6M (est)Nkt Therapeutics Inc · Seed Raised $4.0M · modeled $177.6M (est)Surface Logix Inc · Seed Raised $4.0M · modeled $177.6M (est)Fe3 Medical, Inc. · Seed Raised $5.4M · modeled $177.1M (est)Proteonomix, Inc. · Seed Raised $3.8M · modeled $169.0M (est)SRS Medical Systems, Inc. · Seed Raised $3.8M · modeled $167.4M (est)Origen Therapeutics Inc /Ca · Seed Raised $3.7M · modeled $166.2M (est)Vivebio, LLC · Seed Raised $3.7M · modeled $163.1M (est)O2 Medtech Inc · Seed Raised $7.1M · modeled $160.3M (est)Biothera, Inc. · Seed Raised $3.5M · modeled $155.4M (est)Juneau Biosciences, LLC (this company) Raised $8.1M · modeled $44.4M (est)Juneau Biosciences, LLC
CompanyStageRaised · realValue · estvs peer med.
Denali Medical II, Inc.Seed$4.0M$177.6M2.05×
Signum Biosciences, Inc.Seed$4.0M$177.6M2.05×
Health Elements, LLCSeed$4.0M$177.6M2.05×
Nkt Therapeutics IncSeed$4.0M$177.6M2.05×
Surface Logix IncSeed$4.0M$177.6M2.05×
Fe3 Medical, Inc.Seed$5.4M$177.1M2.05×
Proteonomix, Inc.Seed$3.8M$169.0M1.95×
SRS Medical Systems, Inc.Seed$3.8M$167.4M1.93×
Origen Therapeutics Inc /CaSeed$3.7M$166.2M1.92×
Vivebio, LLCSeed$3.7M$163.1M1.88×
O2 Medtech IncSeed$7.1M$160.3M1.85×
Biothera, Inc.Seed$3.5M$155.4M1.79×
Juneau Biosciences, LLC this companySeed$8.1M$44.4M0.51×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$2.6M2009-03-23$13.0M$115.4M90%
Seed$3.8M2010-05-21$18.8M$167.0M90%
Seed$250K2010-05-21$1.3M$11.1M90%
Seed$500K2011-05-31$2.5M$22.2M90%
Seed$1.0M2011-07-19$5.0M$44.4M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$2.6M2009-03-23
    • First recorded raise — entered as Seed.
  2. Seed$3.8M2010-05-21
    • Raised 14 mo later, in step with the ~14 mo sector norm.
    • Round 1.4× larger than the prior — scaling up.
  3. Seed$250K2010-05-21
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 15.0× smaller than the prior — bridge or down round.
  4. Seed$500K2011-05-31
    • Raised 12 mo later, in step with the ~14 mo sector norm.
    • Round 2.0× larger than the prior — scaling up.
  5. Seed$1.0M2011-07-19
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round 2.0× larger than the prior — scaling up.
Intelligence
2012 ~Q1
Modeled next raise · ~7mo cadence
$2.0M
Modeled next size est.range $1.3M$3.2M
2.0×
Last step-up
$3.5M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Eric Robinson3 other2009-03
Bradley Carling Robinson1 other2010-05
Eric Lamond Robinson1 other2010-05
Kenneth Ward1 other2009-03
Ken Ward1 other2011-05
Hans Albertsen2009-03
Hans Carling Albertsen2010-05
Hans M. Albertsen2011-07
James Marsh2011-05
James M. Marsh2010-05
Lesa M. Nelson2010-05
Lesa Nelson2011-05
Linda Gould2009-03
Rich Linder2011-05
Registry & provenance

Juneau Biosciences, LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1400105
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Pacific Diabetes Technologies, Inc.BiotechnologySeed$9.0M$8.1Mnetwork2 shared operators · same sector · same stage
Sun BioPharma, Inc.BiotechnologySeed$8.0M$52.2Msame sector · same stage
Avotres Inc.BiotechnologySeed$8.0M$37.0Msame sector · same stage
Tamir Biotechnology, Inc.BiotechnologySeed$8.4M$35.9Msame sector · same stage
Launchcyte LlcBiotechnologySeed$7.8M$46.8Msame sector · same stage
MicroPower Global LtdEnergy ConservationSeries A$9.0M$8.9Mnetwork2 shared operators
Tetragenetics IncBiotechnologySeed$7.1M$39.9Msame sector · same stage
Voltron Therapeutics, Inc.BiotechnologySeed$9.4M$39.4Msame sector · same stage
Frequently asked
How much funding has Juneau Biosciences, LLC raised?
Juneau Biosciences, LLC has raised approximately $8.1M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is Juneau Biosciences, LLC's estimated valuation?
Provath's modeled valuation for Juneau Biosciences, LLC is approximately $44.4M (modeled range $720K–$348.4M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Juneau Biosciences, LLC at?
Juneau Biosciences, LLC's latest modeled financing stage is Seed. Its most recent recorded round closed around Tue Jul 19.
What does Juneau Biosciences, LLC do and where is it based?
Juneau Biosciences, LLC operates in the Biotechnology sector, based in Salt Lake City.
Explore related

See where Juneau Biosciences, LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Juneau Biosciences, LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.